Opus Genetics (IRD) EBITDA (2010 - 2026)
Opus Genetics' (IRD) quarterly EBITDA came in at -$14.4 million in Q1 2026, down 44.67% year-on-year from -$26.0 million in Q1 2025, and down 25.42% on a QoQ basis from -$11.5 million in Q4 2025.
Opus Genetics (IRD) EBITDA (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 17 years of EBITDA data on file, last reported at -$14.4 million in Q1 2026.
- On a quarterly basis, EBITDA fell 44.67% year-over-year to -$14.4 million in Q1 2026; TTM through Mar 2026 was -$43.0 million, a 33.07% increase from a year earlier, with the FY2025 full-year figure at -$38.6 million, up 37.82% from the prior year.
- EBITDA for Q1 2026 stood at -$14.4 million, down from -$11.5 million in the prior quarter.
- Over the last five years, EBITDA for IRD reached as high as $34.2 million in Q4 2022 and fell as low as -$38.0 million in Q4 2024.
- Historically, EBITDA has averaged -$6.3 million across 5 years, with a median of -$7.7 million in 2024.
- Across the five-year window, EBITDA jumped 656.26% in 2022 and tumbled 600.48% in 2024, its largest moves.
- Year by year, EBITDA stood at $34.2 million in 2022, then sank by 115.87% to -$5.4 million in 2023, then tumbled by 600.48% to -$38.0 million in 2024, then soared by 69.88% to -$11.5 million in 2025, then slipped by 25.42% to -$14.4 million in 2026.
- Per Business Quant data, the three most recent EBITDA figures were -$14.4 million in Q1 2026, -$11.5 million in Q4 2025, and -$8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Opus Genetics | 3.27 Mn | -56.73 Mn | - | -14.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.36 Mn |
| Dec 31, 2025 | -11.45 Mn |
| Sep 30, 2025 | -8.31 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Mar 31, 2025 | -9.93 Mn |
| Dec 31, 2024 | -38.03 Mn |
| Sep 30, 2024 | -8.01 Mn |
| Jun 30, 2024 | -8.33 Mn |
| Mar 31, 2024 | -7.71 Mn |
| Dec 31, 2023 | -5.43 Mn |
| Sep 30, 2023 | 6.39 Mn |
| Jun 30, 2023 | -5.39 Mn |
| Mar 31, 2023 | -6.13 Mn |
| Dec 31, 2022 | 34.21 Mn |
| Sep 30, 2022 | -4.54 Mn |
| Jun 30, 2022 | -4.94 Mn |
| Mar 31, 2022 | -6.51 Mn |
| Dec 31, 2021 | -6.15 Mn |
| Sep 30, 2021 | -4.23 Mn |
| Jun 30, 2021 | -7.14 Mn |